Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 21, 2023, the Board of Directors of Interpace Biosciences, Inc. (the
"Company") appointed Christopher McCarthy, age 31, who has served as the
Company's Vice President of Finance and Enterprise Systems since August 2022, as
Principal Financial Officer.
Prior to serving as the Company's Vice President of Finance and Enterprise
Systems, Mr. McCarthy served as the Company's Senior Director of Operations
Finance from August 2020 to August 2022 and the Company's Senior Financial
Analyst from June 2019 to August 2020. Prior to joining the Company, Mr.
McCarthy served as a Senior Financial Systems Analyst at Simon & Schuster, Inc.
from January 2016 to June 2019.
Except as described herein, Mr. McCarthy has served in no other Company
positions and there is no arrangement or understanding between Mr. McCarthy and
any other person pursuant to which he was selected to serve as Principal
Financial Officer. Mr. McCarthy has no family relationship with any director or
executive officer or person nominated or chosen by the Company to become a
director or executive officer of the Company. There are no related party
transactions as of the date hereof between Mr. McCarthy and the Company that
would require disclosure under Item 404(a) of Regulation S-K.
© Edgar Online, source Glimpses